The things you need to know about the digital transformation of primary research
In the rapidly evolving market access landscape, it’s important to quickly identify current payer perspectives to determine future trends. High-quality, rapid primary research can be key to fast-forwarding your strategy.
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership
HealthEconomics.Com© LLC and Scientist.Com are partnering to streamline HEOR and real-world evidence sourcing in the global HEOR and RWE community [...]
Blog Post Highlights Impact Coronavirus Could Have on New Drug Launches
A recent blog post on Tribeca Knowledge outlines some of the key challenges pharmaceutical companies face regarding drug launches in [...]
Shkreli Seeks Furlough to Research Potential COVID-19 Treatments
Disgraced biotech entrepreneur Martin Shkreli is requesting a 3-month furlough to research potential treatments for COVID-19, STAT reports. In a [...]
ISPOR 2020 Goes Virtual
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is moving its annual meeting into the virtual space in response [...]
AMCP to Supreme Court: Ruling Against PCMA Could Raise Health Costs
The Academy of Managed Care Pharmacy (AMCP) in an amicus brief filed in the Supreme Court tells the court ruling [...]
MSK’s Bach Talks High-Value Drug Development
Memorial Sloan Kettering Cancer Center's Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value [...]
ISPOR Task Force Publishes New Good Practices Reports
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) Value of Information Analysis Emerging Good Practices Task Force has had [...]
Calculating Costs, Benefits of Lockdowns
How do economists calculate the value of preventing COVID-19 deaths? The authors of a recent article published on Forbes outline [...]
PRMA’s Chadwick Talks Digital Tech’s Impact on Market Access
PRMA Consulting HTA Manager Claire Chadwick outlines how digital technology is changing the face of the market access landscape in [...]
Article Outlines How Health Plans Utilize RWE for Specialty Drug Coverage
Health plans' use of real-world evidence for specialty drug coverage decisions is generally varied in terms of the number and [...]
Waystar: Poor Price Transparency is ‘Single Biggest Issue’ in Patient’s Financial Experience
In a sponsored article on HealthLeaders Media, Waystar outlines the patient's need for more "financial clarity" during their health care [...]
eyeforpharma Philadelphia Pivots to Virtual Event
In response to the COVID-19 outbreak, eyeforpharma is transitioning its eyeforpharma Philadelphia conference to a free, online event. The 4-day [...]
NICE Publishes COVID-19 Guidelines
The National Institute for Health and Care Excellence (NICE) on March 21 published a new set of guidelines that address [...]
Webinar – Faster to Market: Transforming HEOR & RWE Using Virtual Sourcing
Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want [...]
Blog Post Mulls Indirect Benefits in Value Assessments
A recent blog post published on Health Affairs highlights some key reasons why indirect benefits should be factored into value [...]
Predictions for RWE in 2020
A recent article published on PharmaTimes looks at what the future may hold for real-world evidence amid rising interest in [...]
Lin: Clinical Practice Guidelines Not Broken
Family physician and Common Sense Family Doctor blogger Kenneth Lin in a recent post published on MedPage Today writes that [...]
ICER Indefinitely Postpones Public Meetings, Expands Assessment Timelines
In response to the COVID-19 pandemic, the Institute for Clinical and Economic Review (ICER) announced it would indefinitely postpone several [...]
AMCP Cancels Annual Meeting
The Academy of Managed Care Pharmacy (AMCP) has canceled its annual meeting, which was set to begin April 21, saying [...]
Pfizer Offers Its Resources in Fight Against Coronavirus
Pfizer is entering the fight against coronavirus after announcing it would offer its resources for wider use, FiercePharma reports. The [...]
ICER Posts Reports Outlining Two Planned Reviews
The Institute for Clinical and Economic Review (ICER) on Friday, March 13, posted two new draft scoping documents outlining planned [...]
U.S. Looks to Limit Out-of-Pocket Costs for Insulin Under Medicare
The Trump administration announced a new plan to limit the out-of-pocket costs for insulin to $35 month for Medicare patients, [...]
RWE 2020 Postponed Until Later This Year
The Real-World Evidence 2020: Rare Diseases and Innovative Therapies event has been postponed to later this year in response to [...]
Webinar to Outline Key Takeaways of ICER’s Updated Value Framework
Boston Healthcare Associates is slated to highlight the Institute for Clinical and Economic Review's (ICER) updated value assessment framework in [...]